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Current Status of FK 506 in Liver Transplantation 
J.J. Fung, S. Todo. A. Tzakis. M. Alessiani. K. Abu-Elmagd, A. Jain. O. Bronster. M. Martin, A. Gordon. 
and T.E. Starzt 
I N 1987 Ochiai and coworkers presented a repon on the immunosuppressIve qualities of a new immunosup-
pressive agent. FK 506. isolated from the fennented broth 
of a soil fungus. ptr~ptomDlces tsukubaensis. I ExtenSIve in 
vitro studies demonstrated the effectiveness in suppressing 
mixed lymphocyte cultures. presumably by inhibiting lL-2 
synthesis following alloactivation.: The receptor for FK 
506 has been identified and has been characterized as a 
peptidyl-prolyl cis-trans isomerase.) 
The background for the clinic:ai development of FK 506 
was well documented by Starzt in the opening remarks of 
a satellite symposium on FK 506. held in Barcelona. Spain. 
in November 1989 as part of the European Society of 
Organ Transplantation. 4 In vivo studies using a number of 
animal models have shown a marked ability to prevent 
rejection following various types of organ transplants.s.., 
More Interestingly, FK 506 possesses the ability to reverse 
ongoing rejection in animal models.7.1 This charactenstic 
is unique. since it is well known that cyclosporine (CyA) 
will not reverse established ongoing rejection. These prop-
enies served as the initiative to pursue clinical testing of 
FK 506. 
The objective ofthis repon is to update the reader on the 
current status of the use of FK 506 in liver transplantation 
at the University of Pittsburgh. One phase of the study 
consists of the "rescue" with FK 506 of liver allografts 
undergoing rejection with CyA-based immunosuppres-
sion. '1 The second phase of the repon consIsts of the 
results of primary liver transplantation using FK 506. 10 
METHODS 
Study DeSign 
The tnals in laver transplantation were conducted at the Univer· 
\ity of Pittsburgh. Presbytenan University Hospital. Children's 
Hospital of Pittsburgh. and the Veterans Administration Medical 
Center. wllh the approvals of the respective institutional revIew 
boards. informed consent was obtained from patients or their 
aPPOInted guardians. 
Patient Profiles 
1 n the rescue therapy studv. 173 pallents admitted for hepatic 
rejection were convened from CyA to FK 506. Fifty·seven 
patients were diagnosed wnh acute reJection. and 116 pauents 
were dla8l10seG Wllh chronIC reJecllon. Most of the 173 rescue 
pallents were beanng their lirst liver allogra!t at the lime of the 
~onverslon from CyA to FK 506. A smaller number 01 pallents 
had preVIously undergone more than one hver transplantation: 
one patient was carrying Ius fifth liver transplant at the time of FK 
506c:onverslon. in the pnmarv FK 506-treated study. 125 pallents 
received FK 506 and low-dose steroIds as the baseline Immuno-
suppression therapy after liver transplantallon. 
Diagnostic EvaluatiOns 
For patients who were expenencing liver dysfunction. the final 
categorizalJon of the dysfunction was based on clinic:a1. biochem-
ical. and histopathologic findings. For all patients. in both the 
primary and rescue therapy groups. the c:ause or causes of liver 
dysfunction were carefully sought. Ultrasonic detenrunauon of 
vessel patency and radiographic evaluation of the biliary system 
were used to rule out a technical or mechanical defect. Angiog-
raphy was performed when indicated. Appropriate viral cultures 
and stains were used to detect viral infections. Protoc:oj bioJ)sies 
were emJ)loyed to evaluate the efficacy of FK 506 theraJ)y. All 
biopsies were blinded and inte",reted by a single expenenced 
liver pathologist (A.J.D.I. Biopsy spectmens were fixed in neutral 
buffered formalin and stained with hematoxylin-eosin. trichrome. 
and reticulin stains. The cntena used for pathologic diagnosIS 
have been clearly defined in prevIous repons. II 
TIming and Details of Therapy 
Treatment with FK S06 was begun in the hospital and was liven 
initiaJly as a parenteral dose. followed by conversion to an oral 
dose. The initial parenteral dose of FK 506 was 0.075 to 0.15 
mgikg. given intravenously over a penod of 4 hours. This treat-
ment was conllnued until the patient was able to ingest the oral 
fonn of FK 506. Generally. oral dosage of FK 506 was 0.30 m8lkl. 
divided into two doses. Doses of FK 506 were adjusted on the 
basis of serum trough levels monnored by ELISA 12 as well as 
clinical or biochemical vanables, 
EvaluabOn of Response 
Periodic liver funcllon tests. including total bilirubin cTSll). 
serum glutamic transamlnases ISGOT and SGPTI. and alkaline 
phosphatase levels were performed. All values are expressed as 
the mean = SO. Protocol biopSies were obtamed after Iniuauon of 
FK 506 therapy. 
RESULTS 
Rescue Therapy 
In this population of 173 patients. many of whom were 
critic:aily ill at the lime of FK .506 conversIon. a total of 14 
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FIg 1. Total bilirubin values In 57 liver transplant reopien1S with 
acute rejection who were SWItched to FK 506 from cycIosponne. 
deaths were encountered (8.1%). The causes of death were 
numerous. but the incidence of monaJity was directly 
correlated with the medical condition of the patient at the 
time of FK 506 conversion. Sepsis was the cause of death 
in four patients. Three patients died from metastatic car-
cinoma following transplantation. In two patients. retrans-
plantation was not considered an option for the failing liver 
allograft. Three patients died with hemorrhagic complica-
tions. One patient with pathologic findings of late chronic 
rejection died from technical causes during an attempted 
retransplantation. In one death. no clear cause could be 
determined. This patient died at home and had been otT FK 
506 for 4 months when she died. 
The biochemical response of the liver allografts to FK 
506 is reponed by classification of patients as having either 
acute or chromc rejection. Figure I shows the total biliru-
bin and Fig 2 shows the transaminase levels for the 57 
patients who were treated for acute rejection. These levels 
were documented by liver biopsy or as judged by biochem-
Ical and clinical variables. The TBIL. SGOT. and SGPT 
levels pnor to FK 506 were 4.68 ~ 5.91 mgtdL. 240 ~4P1 
lUlL. and 292 ~ 383 lUll. respectively. By the sixth 
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Fig 3. Total bilirubin values in 116 liver transplant recipients with 
chronic rejection who were SWItched to FK 506 from cycIosponne. 
month these values dropped to 0.76 ~ 1.41 mg/dL. 98 ~ 
163 lUlL. and 90 ± 128 lUlL. respectively. 
Patients with an entrance diagnosis of chronic rejection 
also had a beneficial response to FK 506. Figure 3 shows 
the total bilirubin and Fig 4 shows the transaminase levels 
for the 116 patients treated for this speCific indication. The 
total bilirubin decreased to nonnal values (pre-FK 506. 
5.07 :!: 8.16 mg/dL: after 6 months. 0.99 ± 1.47 mgldU 
while the average transaminase values were stiU slightly 
above normal values (pre-FK 506. SGOT/SGPT. 200 ~ 
1751275 ~ 223 lUll: after 6 months. SGOT/SGPT. 44 1: 
721101 ~ 68 lUlL). 
In each case where histopathologic changes were pre· 
dominant. the influence of FK 506 on the initial findings of 
rejection or hepatitis could be evaluated in senal follow-up 
biopsies. Overall. 17% of the biopSies with a diagnosis of 
rejection showed worsening of the pathology; 36% of the 
liver biopsies showed no pathologic changes between the 
pre-FK 506 biopsy and the 2·month follow-up biopsy; and 
47% of the remaining biopSies showed improvement be· 
tween the initial and follow-up biopSies. These changes 
were panlcularly impreSSive In patients whose pretreat-
ment biopsies contained bile duct lesions that generally 
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Fig 2. SGOT and SGPT values 
In 57 liver transplant reaplenlS 
With acute re,ectIOn after conver· 
sion to FK 506. 
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Fig 4. SGOT and SGPT values 
in 116 liver transplant r9CIp!8fllS 
with chronic reJ8diOn after con-
version to FK 506. 
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progress to bile duct disappearance and graft loss. despite 
intensive immunosuppression. 
Primary FK 506 Treatment After Liver Transplantation 
Ten of the 125 patients died. for a survival rate of 92% after 
6 to 12 months. When compared with 325 sequential liver 
transplantations during the preceding year before FK 506. 
the results are significantly better statistically in terms of 
patient and graft survival (Fig 5). This trend was seen in 
both the adult population (110 patients) and the pediatric 
population (15 patients). although the number of pediatric 
patients in the trial was too small to achieve statistical 
significance. Of the 10 deaths. 5 were due to sepsis. I to 
hean failure. I to a cerebral vascular accident. 2 to 
nonreversible hepatic coma. and I to technical complica-
tions. 
During the follow-up penod. 50% of all recipients were 
taken off steroids and were maintained on single-drug 
immunosuppression with FK 506. Yet 52.8% of all patients 
were rejection-free during the enure penod of study. Most 
uf the rejection episodes were mild and easily controlled 
with a smgle dose of bolus steroids (either methylprednis-
olone or hydroconisonel. Only 17.8% of the rejection 
episodes reqUired funher steroid treatment in the form of a 
steroid taper or additional slerold boluses. In addition. 
only 11.2% of the patients reqUired OKTI. The inCidence 
of serious infections. despite the potency of FK 506. has 
not appeared to be alarming. The incidence of serious 
mfections was about 50% less than seen in a histoncai 
group of pauents given CyA. Of note IS that the incidence 
of cytomegalovirus infections did not appear to be in· 
creased when compared with pallents on Cy A. 
DISCUSSION 
Cyc1osponne·based immunosuppression significanlly en· 
hanced both pallent and graft SUrvIval. when compared 
with the era of azathioprine and steroids. Il Nevenheless. 
most centers experience a 40% to 50% I·year grait loss and 
~% to 30% patient within the first-year loss. The most 
common complicaung factor has been the development of 
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rejection. occurring in over 70% of all CyA-treated pa-
tients. In addition. the sequela caused by overimmunosup-
pression. such as the excessive use of steroids or anti-
lymphocyte preparations. have a high incidence of 
infectious complications. It stands to reason that a baseline 
immunosuppressive agent that allows a lower incidence 
and easier treatment of rejection would decrease both graft 
and patient loss. From the results of our preliminary 
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Fig 5. Life sUMVsl curves for pnmary lIVer transplantallOn reco-
ianlS gIVen FK S06 an<! cycIOSponne. 
FK 50S IN LIVER Tx 
studies presented here. the use of FK 506 in liver trans-
plantation has these advantages. The use of FK 506 
appears not only to decrease the absolute incidence of 
rejection episodes. allowing a marked reduction in steroid 
doses. but also to make the treatment of rejection much 
simpler. The requirement for 0 KT3 in liver transplantatIon 
has decreased by 50%. 
The ability of a new immunosuppressive agent to be 
dose-adjustable for treatment of acute and chronic rejec-
tion would represent an important facet. ascribed only to 
steroids in the past. Thus. FK S06 can be used in this 
manner. In fact. the first response to a developing rejection 
is to increase the baseline dose of FK 506. In rescue 
therapy. the marked ability of FK 506 to reverse both 
acute and chronic rejection has not been seen with any 
immunosuppressive agent in the past. While the mccha-
nism by which FK 506 is able to do this is not known. it 
would appear that it would entail mechanisms other than 
simply inhibition of IL-2 synthesis. FK S06 has been 
shown to be a potent hepatotrophic agent. 14•15 Liver 
allografts in end-stage chronic rejection can be rescued in 
60% to 70% of the cases.9 
The Food and Drug Administration will require further 
substantiation of the efficacy of FK S06 in multicenter 
trials. Prospective. randomized trials comparing FK S06 
therapy with Cy A-based immunosuppression are currently 
underway. These studies will help identify areas in which 
FK 506 may be more advantageous. or more disadvanta-
geous. than current methods of immunosuppression. A 
well-defined endpoint. other than patient or graft loss. 
should be utilized. since the data presented here also 
1905 
suggest that a conversion to FK S06 might salvage liver 
allograits in danger of being lost to rejcction. Future trials 
eumining the role of FK S06 in liver allograft rejection are 
being devised either separately from the primary trials or. 
perhaps. as part of the pnmary trials. 
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